APP announces clearance
Schaumburg-based APP Pharmaceuticals Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding Inc. announced that it has received clearance from the U.S. Food and Drug Administration to market preservative-free Heparin Lock Flush Solution, USP in two dosage strengths, 10 USP Units/1 mL and 100 USP Units/1 mL, and will soon launch these single dose vial presentations.
APP is a consistent supplier of heparin to the marketplace and this approval provides health care professionals with the only preservative-free Heparin Lock Flush Solution in a single dose vial.
Benzyl alcohol has been associated with toxicity in neonates and has been reported to be associated with a fetal "Gasping Syndrome" in premature infants.
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked.
If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.